Has William Mihalko, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,999,471 in general payments to William Mihalko, MD across 204 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean William Mihalko, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about William Mihalko, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

William Mihalko, MD

Orthopaedic Surgery · Charlottesville, VANPI 1013086644

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $1,633,219 of the $1,999,471 with a category attached, or 81.7%. Aesculap AG accounts for 81.7% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $409,700, 2.2 times the $187,758 reported in 2019. Among orthopaedic surgery clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,999,471in general payments, 2019–2025

Across 204 payments — averaging $9801.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Aesculap AG$1.6M
Aesculap Implant Systems, LLC$281K
Pacira Pharmaceuticals Incorporated$50K
Aesculap, Inc.$30K
Stryker$3K
Medacta USA, Inc.$370
plus $790 from 9 others

$141,277in research payments, 2019–2025

Across 4 payments — averaging $35,319 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medacta USA, Inc.$126K
Pacira Cryotech Incorporated$11K
Myoscience Inc.$4K
Aesculap Implant Systems, LLC$75

What the payments were for

Royalty or licence$1,633,21982%
Consulting fees$274,63214%
Speaking & faculty fees$66,2933%
Travel & lodging$21,1161%
Food & beverage$4,1160%
Education$960%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Aesculap AG	53	$1,633,923
Aesculap Implant Systems, LLC	91	$280,740
Pacira Pharmaceuticals Incorporated	20	$50,293
Aesculap, Inc.	3	$30,240
Stryker	19	$3,115
Medacta USA, Inc.	4	$370
Johnson & Johnson	2	$142
Smith+Nephew	3	$137
Davol Inc.	1	$135
Myoscience Inc.	1	$107
Sanara Medtech Inc.	2	$100
Zimmer Biomet	1	$96
Ferring Pharmaceuticals Inc.	2	$31
Kerecis Limited	1	$21
Bioventus LLC	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,999,471 in reported general payments places this provider in the 95th percentile of 473 orthopaedic surgery providers in Virginia.

See all orthopaedic surgery providers in Virginia →

Medicare billing

Part B allowed, 2024

$182,434

Medicare patients

418

Services billed

7,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Methylprednisolone	114	$822
Celecoxib	15	$256
Meloxicam	55	$183
Gabapentin	12	$155
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	15	$92
Tramadol Hcl	24	$81
Oxycodone Hcl	11	$75
Naproxen	16	$56
Cephalexin	11	$29
Ondansetron Hcl	15	$27

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Charlottesville

Cato LaurencinCharlottesville$3.5M
Stephen GuntherCharlottesville$545K
Adam ShimerCharlottesville$303K
Charles SuCharlottesville$47K
Dale YoungNorth Chesterfield$10.9M
James DowdVirginia Beach$6.1M
Mark de BloisNorth Chesterfield$4M
Randall PeytonSterling$2.9M
David MillerNorth Chesterfield$1.7M
Keith LawhornFairfax$1.6M

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →